Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia Day Two Might Be Same Old Song Even With Broken RECORD

This article was originally published in The Pink Sheet Daily

Executive Summary

There may be more at stake for FDA, and the pharmaceutical industry in general, in how the advisory committees interpret the RECORD trial than there is for Avandia itself.

You may also be interested in...



Sentinel Initiative Needs Better Defined Goals, Outside Review Concludes

The Pharmacovigilance Review Subcommittee of FDA's Science Board reports a lack of clarity within CDER over just what purpose the drug safety program is supposed to serve.

Sentinel Initiative Needs Better Defined Goals, Outside Review Concludes

The Pharmacovigilance Review Subcommittee of FDA's Science Board reports a lack of clarity within CDER over just what purpose the drug safety program is supposed to serve.

FDA Policy On Financial Conflicts Of Public Speakers At Advisory Panels Unchanged

In final guidance, the agency has rejected calls by the advocacy group Public Citizen to allow committee members to question open public hearing speakers on their finances.

Related Content

Topics

UsernamePublicRestriction

Register

PS070883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel